Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Cancer Specialists
Fort Myers, Florida, United States
- Northeast Georgia Medical Center
Gainesville, Georgia, United States
- Wellstar Cancer Research
Marietta, Georgia, United States
- Kansas City Cancer Centers
Overland Park, Kansas, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, United States
- Methodist Cancer Center
Omaha, Nebraska, United States
- Cancer Care of Western North Carolina
Asheville, North Carolina, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- Mid Ohio Oncology/hematology, Inc./ the Mark H. Zangmeister Center
Columbus, Ohio, United States
- South Carolina Oncology Associates, Pa
Columbia, South Carolina, United States
- Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States
- Family Cancer Center
Collierville, Tennessee, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Coastal Bend Cancer Center
Corpus Christi, Texas, United States
- Virginia Cancer Institute
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2008
- Primary completion
- 28 Feb 2009
- Completion
- 28 Feb 2009
- Last update posted
- 10 Mar 2022
- Registered enrollment
- 166
- Registry id
- NCT00600015
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.